The Vaccine Task Force is a rainbow team, calling upon skills from industry, public sector and consultancies. PA were responsive, and the speed and quality of their work was key to us, says Ruth Todd (CBE), Programme Director, VTF. At every pressure point – and there were many – we could count on their commitment, energy and expert insight. PA were an essential part of our team.
At this point, no-one knew which initiatives would produce a viable vaccine – if at all. On the advice of VTF chair Kate Bingham, the Government had determined to back a wide range of projects. Our business case expertise was instrumental in informing the decisions on which ones and securing the necessary funding.
Working at pace, we translated scientific recommendations, clinical and commercial advantages, negotiating positions and funding requirements into a set of high-quality business cases. This was a shifting landscape. As different vaccines made their way through clinical trials, and safety and efficacy results came out, the risk profile for each potential vaccine shifted. Similarly, demand for individual vaccines surged or dropped away on the back of trial results.
In this high-stakes environment, the team compressed the usual timeline from business case development to ministerial approval from months into weeks, and then from days into hours. We didn’t miss a beat.